The treatment of oncological diseases has developed very positively over the last 20 years. Nevertheless, it is useful to think about what can be used differently or better in standard therapy. In spite of this, not all new therapies for improving the immune system have a good effect in all tumour patients. The reasons for the lack of the expected response to treatment are the subject of much research today. One new direction is the use of modified bacteria and viruses both to activate the immune response and to make it more targeted. The fact that this is possible was noticed more than 100 years ago and the treatment of tumours by injecting pathological bacteria into the tumour was initiated. This is an oncological treatment complex that contains a combination of complementary, naturopathic treatment methods and new forms of treatment such as checkpoint inhibitors as well as some elements of conventional therapies. All this against the background of the strong activation of the immune system with PAMP therapy. The treatment method and the course of recovery are described here and also presented using two practical examples. This concept is not only able to positively influence the course of the disease even in moderately advanced stages of a tumour disease, but is even able to cure many of those who are supposedly incurable. For this purpose, only special oncolytic viruses and modified bacteria should not necessarily be used for such therapies. Vaccinations from living weakened bacteria and viruses used in other ways also ensure sufficient and successful activation of the immune system. Particular attention is paid to the safety of the therapy and the avoidance of drug interactions. The proposed concept has shown high therapeutic potential in various cancers. Many details of the method's application require further observation and subsequent analysis.
| Published in | Science Journal of Public Health (Volume 13, Issue 3) |
| DOI | 10.11648/j.sjph.20251303.12 |
| Page(s) | 114-122 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
Anticancer Immunity, Natural Killer Cells, Immunstimulation, PAMP Therapy, Tumor Antigens
| [1] | Apetoh L., Ghiringhelli F., Tesniere A. et all. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med, 2007; |
| [2] | Micksche M., Kokoschka E M, Sagaster P, et al. Klinische und immunologische Untersuchungen mit OK-432 (Streptococcus pyogenes) zur Immuntherapie bei Krebspatienten. Onkologie, 1978; |
| [3] | Schorr-Tschudnowski M. Konzept einer komplexen Tumortherapie mit kurativem Anspruch auch in fortgeschrittenen Stadien. Erfahrungsheilkunde, 2023, |
| [4] | Mühlebach M. D. Measles virus in cancer therapy. Curr Opin Virol 2020, |
| [5] | Hobohm U, Stanford JL, Grange JM. Pathogen-associated molecular pattern in cancer immunotherapy. Crit Rev Immunol. 2008, |
| [6] | Balar A. V., Galsky M. D., Rosenberg J. E. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017, |
| [7] | Forcic D, Mrcic K, Peric-Balja M. et al. Eine unkonventionelle Fallstudie zur neoadjuvanten Onkolytika-Virotherapie für wiederkehrenden Brustkrebs. Vaccines 2024, |
| [8] | Torcellan T, Friedrich C, Doucet-Ladevèze R. et al. Circulating NK cells establish tissueresidency upon acute infection of skin and mediate accelerated effector responses to secondary infection. Immunity. 2024, |
| [9] | M. Dabrowski, B. Dabrowski-Bernstein: Immunoregulatory Role of Thymus, CRC Press 1990, S. 154. |
| [10] | Hongu T. Pein M., Insua-Rodríguez J. et al.: Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs. Nat Cancer, 2022; |
| [11] | Galluzzi L., Humeau J., Buqué A. et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol, 2020; |
| [12] | Sharma P, Stecklein SR, Yoder R et al. Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC). Journal of Clinical Oncology, 2022, |
| [13] | Plate, J., Plate A., Shott S. et al. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother, 2005; |
| [14] | Hajto T. New Perspectives to Improve the MHC-I Unrestricted Immune Mechanisms against Malignant Tumors. Adv Clin Transl, 2018; Res 2: 100014. |
| [15] | Dean I., Colin Y. C., Zewen K. T. et al. (2024) Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity. Nature Communications, |
| [16] | Erqi L. Pollom, George A. Fisher Jr., Andrew Shelton et al. Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX). 2024, ASCO Annual Meeting I, |
APA Style
Schorr-Tschudnowski, M. (2025). The Concept of Complex Tumour Therapy with a Tendency Towards Convalescence. Science Journal of Public Health, 13(3), 114-122. https://doi.org/10.11648/j.sjph.20251303.12
ACS Style
Schorr-Tschudnowski, M. The Concept of Complex Tumour Therapy with a Tendency Towards Convalescence. Sci. J. Public Health 2025, 13(3), 114-122. doi: 10.11648/j.sjph.20251303.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sjph.20251303.12,
author = {Moses Schorr-Tschudnowski},
title = {The Concept of Complex Tumour Therapy with a Tendency Towards Convalescence
},
journal = {Science Journal of Public Health},
volume = {13},
number = {3},
pages = {114-122},
doi = {10.11648/j.sjph.20251303.12},
url = {https://doi.org/10.11648/j.sjph.20251303.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjph.20251303.12},
abstract = {The treatment of oncological diseases has developed very positively over the last 20 years. Nevertheless, it is useful to think about what can be used differently or better in standard therapy. In spite of this, not all new therapies for improving the immune system have a good effect in all tumour patients. The reasons for the lack of the expected response to treatment are the subject of much research today. One new direction is the use of modified bacteria and viruses both to activate the immune response and to make it more targeted. The fact that this is possible was noticed more than 100 years ago and the treatment of tumours by injecting pathological bacteria into the tumour was initiated. This is an oncological treatment complex that contains a combination of complementary, naturopathic treatment methods and new forms of treatment such as checkpoint inhibitors as well as some elements of conventional therapies. All this against the background of the strong activation of the immune system with PAMP therapy. The treatment method and the course of recovery are described here and also presented using two practical examples. This concept is not only able to positively influence the course of the disease even in moderately advanced stages of a tumour disease, but is even able to cure many of those who are supposedly incurable. For this purpose, only special oncolytic viruses and modified bacteria should not necessarily be used for such therapies. Vaccinations from living weakened bacteria and viruses used in other ways also ensure sufficient and successful activation of the immune system. Particular attention is paid to the safety of the therapy and the avoidance of drug interactions. The proposed concept has shown high therapeutic potential in various cancers. Many details of the method's application require further observation and subsequent analysis.
},
year = {2025}
}
TY - JOUR T1 - The Concept of Complex Tumour Therapy with a Tendency Towards Convalescence AU - Moses Schorr-Tschudnowski Y1 - 2025/05/29 PY - 2025 N1 - https://doi.org/10.11648/j.sjph.20251303.12 DO - 10.11648/j.sjph.20251303.12 T2 - Science Journal of Public Health JF - Science Journal of Public Health JO - Science Journal of Public Health SP - 114 EP - 122 PB - Science Publishing Group SN - 2328-7950 UR - https://doi.org/10.11648/j.sjph.20251303.12 AB - The treatment of oncological diseases has developed very positively over the last 20 years. Nevertheless, it is useful to think about what can be used differently or better in standard therapy. In spite of this, not all new therapies for improving the immune system have a good effect in all tumour patients. The reasons for the lack of the expected response to treatment are the subject of much research today. One new direction is the use of modified bacteria and viruses both to activate the immune response and to make it more targeted. The fact that this is possible was noticed more than 100 years ago and the treatment of tumours by injecting pathological bacteria into the tumour was initiated. This is an oncological treatment complex that contains a combination of complementary, naturopathic treatment methods and new forms of treatment such as checkpoint inhibitors as well as some elements of conventional therapies. All this against the background of the strong activation of the immune system with PAMP therapy. The treatment method and the course of recovery are described here and also presented using two practical examples. This concept is not only able to positively influence the course of the disease even in moderately advanced stages of a tumour disease, but is even able to cure many of those who are supposedly incurable. For this purpose, only special oncolytic viruses and modified bacteria should not necessarily be used for such therapies. Vaccinations from living weakened bacteria and viruses used in other ways also ensure sufficient and successful activation of the immune system. Particular attention is paid to the safety of the therapy and the avoidance of drug interactions. The proposed concept has shown high therapeutic potential in various cancers. Many details of the method's application require further observation and subsequent analysis. VL - 13 IS - 3 ER -
Medical Office, Frankfurt, Germany
